Terms: = Astrocytoma AND EGFR, mENA, 1956, ENSG00000146648, P00533, ERBB1, ERBB
1984 results:
1. A DTI-based radiomics model for predicting epidermal growth factor receptor (egfr) amplification in adult IDH1-wild glioblastomas.
Wang D; Han Q; Yang S; Cui J; Xia W; Lu Y; Yin B; Geng D
Acta Radiol; 2024 Oct; 65(10):1291-1299. PubMed ID: 39411882
[TBL] [Abstract] [Full Text] [Related]
2. A novel protein SPECC1-415aa encoded by N6-methyladenosine modified circSPECC1 regulates the sensitivity of glioblastoma to TMZ.
Wei C; Peng D; Jing B; Wang B; Li Z; Yu R; Zhang S; Cai J; Zhang Z; Zhang J; Han L
Cell Mol Biol Lett; 2024 Sep; 29(1):127. PubMed ID: 39333871
[TBL] [Abstract] [Full Text] [Related]
3. Prospective Molecular Targets for Natural Killer Cell Immunotherapy against Glioblastoma Multiforme.
Cooksey LC; Friesen DC; Mangan ED; Mathew PA
Cells; 2024 Sep; 13(18):. PubMed ID: 39329751
[TBL] [Abstract] [Full Text] [Related]
4. The Impact of Extensive Surgical Resection of Butterfly Glioblastomas on Outcomes in the Presence of TERT Mutation and egfr Amplification: A Retrospective Cohort Study.
Hekimoglu M; Basak AT; Akgun MY; Ozer H; Ozgen U; Maleki R; Saban D; Oktenoğlu T; Ozer AF; Sasani M
Cancer Control; 2024; 31():10732748241288121. PubMed ID: 39327682
[TBL] [Abstract] [Full Text] [Related]
5. The role of molecular biomarkers in recurrent glioblastoma trials: an assessment of the current trial landscape of genome-driven oncology.
van Opijnen MP; de Vos FYF; Cuppen E; Geurts M; Maas SLN; Broekman MLD
Med Oncol; 2024 Sep; 41(11):250. PubMed ID: 39316248
[TBL] [Abstract] [Full Text] [Related]
6. Glioma nanotherapy: Unleashing the synergy of dual-loaded DIM and TMZ.
Sarkar S; Kumar S; Saha G; Basu M; Ghosh MK
Int J Pharm; 2024 Nov; 665():124697. PubMed ID: 39270762
[TBL] [Abstract] [Full Text] [Related]
7. Therapeutic Efficacy of IL7/CCL19-Expressing CAR-T Cells in Intractable Solid Tumor Models of Glioblastoma and Pancreatic Cancer.
Ohta K; Sakoda Y; Adachi K; Shinozaki T; Nakajima M; Yasuda H; Nagano H; Tamada K
Cancer Res Commun; 2024 Sep; 4(9):2514-2524. PubMed ID: 39240078
[TBL] [Abstract] [Full Text] [Related]
8. Chromosomal instability: a key driver in glioma pathogenesis and progression.
Mazzoleni A; Awuah WA; Sanker V; Bharadwaj HR; Aderinto N; Tan JK; Huang HYR; Poornaselvan J; Shah MH; Atallah O; Tawfik A; Elmanzalawi MEAE; Ghozlan SH; Abdul-Rahman T; Moyondafoluwa JA; Alexiou A; Papadakis M
Eur J Med Res; 2024 Sep; 29(1):451. PubMed ID: 39227895
[TBL] [Abstract] [Full Text] [Related]
9. Importance of Autophagy Regulation in Glioblastoma with Temozolomide Resistance.
Hwang YK; Lee DH; Lee EC; Oh JS
Cells; 2024 Aug; 13(16):. PubMed ID: 39195222
[TBL] [Abstract] [Full Text] [Related]
10. Glioma lateralization: Focus on the anatomical localization and the distribution of molecular alterations (Review).
Cini NT; Pennisi M; Genc S; Spandidos DA; Falzone L; Mitsias PD; Tsatsakis A; Taghizadehghalehjoughi A
Oncol Rep; 2024 Oct; 52(4):. PubMed ID: 39155859
[TBL] [Abstract] [Full Text] [Related]
11. PTBP1-mediated repression of neuron-specific CDC42 splicing constitutes a genomic alteration-independent, developmentally conserved vulnerability in IDH-wildtype glioblastoma.
Yang J; Feng J; Lv J; Chu X; Wei Y; Zhang Y; Li J; Sun Y; Li G; Jiang T; Huang J; Fan X
Funct Integr Genomics; 2024 Aug; 24(4):135. PubMed ID: 39117866
[TBL] [Abstract] [Full Text] [Related]
12. Kinetic Trajectories of Glucose Uptake in Single Cancer Cells Reveal a Drug-Induced Cell-State Change Within Hours of Drug Treatment.
Kim J; Ng RH; Liang J; Johnson D; Shin YS; Chatziioannou AF; Phelps ME; Wei W; Levine RD; Heath JR
J Phys Chem B; 2024 Aug; 128(33):7978-7986. PubMed ID: 39115241
[TBL] [Abstract] [Full Text] [Related]
13. Predicting recurrent glioblastoma clinical outcome to immune checkpoint inhibition and low-dose bevacizumab with tumor in situ fluid circulating tumor DNA analysis.
Guo G; Zhang Z; Zhang J; Wang D; Xu S; Liu G; Gao Y; Mei J; Yan Z; Zhao R; Wang M; Li T; Bu X
Cancer Immunol Immunother; 2024 Aug; 73(10):193. PubMed ID: 39105794
[TBL] [Abstract] [Full Text] [Related]
14. Armored bicistronic CAR T cells with dominant-negative TGF-β receptor II to overcome resistance in glioblastoma.
Li N; Rodriguez JL; Yin Y; Logun MT; Zhang L; Yu S; Hicks KA; Zhang JV; Zhang L; Xie C; Wang J; Wang T; Xu J; Fraietta JA; Binder ZA; Lin Z; O'Rourke DM
Mol Ther; 2024 Oct; 32(10):3522-3538. PubMed ID: 39086131
[TBL] [Abstract] [Full Text] [Related]
15. Genomics and proteomics to determine novel molecular subtypes and predict the response to immunotherapy and the effect of bevacizumab in glioblastoma.
Luo D; Luo A; Hu S; Ye G; Li D; Zhao H; Peng B
Sci Rep; 2024 Jul; 14(1):17630. PubMed ID: 39085480
[TBL] [Abstract] [Full Text] [Related]
16. Formation of egfrwt/egfrvIII homo- and hetero-dimers in glioblastoma cells as detected by single molecule localization microscopy.
Jahnke K; Struve N; Hofmann D; Gote MJ; Bach M; Kriegs M; Hausmann M
Nanoscale; 2024 Aug; 16(32):15240-15255. PubMed ID: 39073345
[TBL] [Abstract] [Full Text] [Related]
17. Discovery of a Therapeutic Agent for Glioblastoma Using a Systems Biology-Based Drug Repositioning Approach.
Kaynar A; Ozcan M; Li X; Turkez H; Zhang C; Uhlén M; Shoaie S; Mardinoglu A
Int J Mol Sci; 2024 Jul; 25(14):. PubMed ID: 39063109
[TBL] [Abstract] [Full Text] [Related]
18. Radiolabeling and Preclinical Evaluation of Therapeutic Efficacy of
Wichmann CW; Morgan KA; Cao Z; Osellame LD; Guo N; Gan H; Reilly E; Burvenich IJG; O'Keefe GJ; Donnelly PS; Scott AM
J Nucl Med; 2024 Sep; 65(9):1456-1462. PubMed ID: 39054282
[TBL] [Abstract] [Full Text] [Related]
19. A syngeneic spontaneous zebrafish model of
Weiss A; D'Amata C; Pearson BJ; Hayes MN
Elife; 2024 Jul; 13():. PubMed ID: 39052000
[TBL] [Abstract] [Full Text] [Related]
20. Mutations in glioblastoma proteins do not disrupt epitope presentation and recognition, maintaining a specific CD8 T cell immune response potential.
Tarabini RF; Fioravanti Vieira G; Rigo MM; de Souza APD
Sci Rep; 2024 Jul; 14(1):16721. PubMed ID: 39030304
[TBL] [Abstract] [Full Text] [Related]
[Next]
